^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MET expression

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
8d
Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. (PubMed, Clin Cancer Res)
Our study establishes that the MUC5AC/cMET/CD44v6 axis is critical for BCBrM, and blocking this axis will be a novel therapeutic approach for BCBrM.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • HGF (Hepatocyte growth factor) • MUC5AC (Mucin 5AC)
|
MET expression
|
bozitinib (APL-101)
9d
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. (PubMed, Cell Rep Med)
The abundant expression of cellular MET (c-MET) in cancer cells has provided new opportunities for immuno-oncology approaches in a broader patient population, and the integration of MET-targeted personalized medicine with immunotherapy has not been fully exploited yet. Here, we highlight essential facets of MET as a therapeutic target in NSCLC and provide an outlook for future approaches.
Review • Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation • MET expression
10d
Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients. (PubMed, Front Biosci (Landmark Ed))
We divided the results by subsite for markers: lymph node analysis (microRNAs, myosin-5a (MYO5A), ring finger protein 145 (RNF145), F-box only protein 32 (FBXO32), CTONG2002744, cytokeratin 14 (CK14), eukaryotic initiation factor 4E (eIF4E), desmoglein-3 (DSG3), microsatellite D9S171, squamous cell carcinoma antigen, cytokeratin, tumor budding score, human papillomavirus-DNA (HPV-DNA), tumor infiltrating lymphocytes, sentinel lymph node analysis techniques, single fiber reflectance spectroscopy, radiological techniques), tumor tissue analysis (activin A, carcinoma-associated fibroblasts, cyclins, β-catenin, histopathology, genetic amplifications, DNA methylation, ecotropic viral integration site 1, CC-chemokine receptor 7, melanoma associated-A antigens, vascular endothelial growth factor-C (VEGF-C), panitumumab, epidermal growth factor receptor (EGFR), cornulin, total protein analysis, CD133, NANOG homeobox, neurogenic locus notch homolog protein 1 (NOTCH1), metastasis-associated protein 1, 14-3-3-zeta, E-cadherin, focal adhesion kinase, p-epithelial-mesenchymal transition (EMT), small proline rich protein 1B (SPRR1B), transcription factor NKX3-1, DNA copy number aberrations, microfibril-associated protein 5 (MFAP5), troponin C1, slow skeletal and cardiac type (TNNC1), matrix Gla protein (MGP), fibroblast growth factor binding protein 1 (FBFBP1), F-box protein 32 (FBXO32), fatty acid binding protein 5, B cell-specific Moloney murine leukemia virus integration site 1, podoplanin, p53, Bcl-2, epidermal growth factor receptor (EGFR), Ki67, cyclin D1, cox-2, semaphorin-3F, neuropilin-2, histologic features, cellular dissociation grade, prospero homeobox protein 1, radiologic features, Ki-67, poly (ADP-ribose) polymerase (PARP), Bcl-2 associated agonist of cell death (BAD), caspase-9, vascular endothelial growth factor A (VEGF-A), HPV, p16, methylation status of long interspersed element 1 (LINE-1) and Alu elements, mesenchymal-epithelial transition (MET), gene expression analyses, molecular subtypes) and blood markers (standard blood analysis indexes and ratios, circulating tumor cells, HPV-DNA, CD-31, bone marrow analysis). Several promising markers were identified, including miR-205, desmoglein 3 (DSG3), pan-cytokeratin (CK) AE1/AE3, HPV-16, activin-A, cyclin D1, E-cadherin, and neural progenitor lineage (NPL) that demonstrated effectiveness across multiple studies. Future research should focus on exploring combination scoring systems to improve diagnostic precision and optimize treatment selection in HNSCC patients.
Review • Journal • PARP Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDH1 (Cadherin 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • MECOM (MDS1 And EVI1 Complex Locus) • VEGFC (Vascular Endothelial Growth Factor C) • FGF (Fibroblast Growth Factor) • CASP9 (Caspase 9) • CD31 (Platelet and endothelial cell adhesion molecule 1) • NANOG (Nanog Homeobox) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • FABP5 (Fatty Acid Binding Protein 5) • FBXO32 (F-Box Protein 32) • MGP (Matrix Gla Protein) • MIR205 (MicroRNA 205) • NKX3-1 (NK3 homeobox 1)
|
MET expression
|
Vectibix (panitumumab)
11d
CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=701, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2025 --> Jun 2026
Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation
|
Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
13d
Early Enhancement in Contrast-Enhanced Computed Tomography Is an Index of DUSP9, SLPI, ALDH1L2, and SLC1A1 Expression in Canine Hepatocellular Carcinoma: A Preliminary Study. (PubMed, Vet Sci)
Canine HCC may involve different angiogenesis mechanisms. CT findings can be used to assess the gene expression status in canine HCC and may add new value to CT imaging.
Journal
|
DUSP9 (Dual Specificity Phosphatase 9)
|
MET expression
13d
Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma. (PubMed, Int J Mol Sci)
Moreover, MET expression was decreased in HSF4-knockdown cells but elevated in sunitinib-resistant RCC cells...Furthermore, HSF4 knockdown combined with an ICI showed synergistic suppression of tumor growth in vivo. Overall, our strategy involving HSF4 knockdown may enhance the efficacy of existing therapies, such as cabozantinib and ICIs.
Journal • Checkpoint inhibition • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • TCF4 (Transcription Factor 4) • HSF4 (Heat Shock Transcription Factor 4)
|
MET expression
|
sunitinib • Cabometyx (cabozantinib tablet)
14d
The Impact of MET Variants in Oral Cancer Progression and Clinicopathological Characteristics. (PubMed, J Cancer)
In the TCGA database, the MET expressions were upregulated in oral cancer tissues compared to normal tissues, and were correlated with poor cell differentiated and poorer prognoses in smoker groups. In conclusion, these novel findings underscore the role of MET genetic variants in oral cancer susceptibility, particularly in smokers, and highlight the potential of these variants for prognosis and disease prediction.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
26d
The Olive Oil Phenolic S-(-)-Oleocanthal Suppresses Colorectal Cancer Progression and Recurrence by Modulating SMYD2-EZH2 and c-MET Activation. (PubMed, Nutrients)
The SMYD2-EZH2 expressions and c-MET activation were notably suppressed by OC treatments in vitro and in collected animal primary tumors. OC and olive phenolics are potential nutraceutical interventions useful for CRC control and the prevention of its relapse.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SMYD2 (SET And MYND Domain Containing 2)
|
KRAS mutation • MET expression
28d
Preclinical Evaluation of 68Ga-Labeled SL1 Aptamer for c-Met Targeted PET Imaging. (PubMed, Mol Pharm)
The probe effectively imaged c-Met-positive tumors and demonstrated a favorable metabolism profile and targeting performance in non-small cell lung cancer (NSCLC) or colorectal cancer tumor models. Consequently, this probe shows promise as an imaging agent capable of providing valuable diagnostic insights into tumors with aberrant c-Met expression.
Preclinical • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression • MET positive
2ms
New P4 trial
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET overexpression • MET expression
|
Haiyitan (gumarontinib)
2ms
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib. (PubMed, Ann Oncol)
Teliso-V plus osimertinib had promising activity and a manageable safety profile in patients with c-Met protein-overexpressing, EGFR-mutated non-squamous NSCLC after progression on osimertinib. This combination has the potential to address an unmet medical need in this patient population.
P1 data • Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • MET overexpression • MET mutation • MET expression
|
Tagrisso (osimertinib) • telisotuzumab vedotin (ABBV-399)
2ms
PAPMET: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (clinicaltrials.gov)
P2, N=152, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET mutation • MET expression
|
Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)
2ms
Coptisine inhibits esophageal carcinoma growth by modulating pyroptosis via inhibition of HGF/c-Met signaling. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Tumor xenograft experiments demonstrated that coptisine effectively inhibited tumor growth by reducing the levels of pyroptosis-associated proteins. In conclusion, these findings indicate that inhibition of the HGF/c-Met signaling pathway suppresses pyroptosis to enhance the antitumor effect of coptisine in ESCC and support the potential use of coptisine for EC treatment.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MIR21 (MicroRNA 21)
|
MET expression
2ms
New trial
|
MET expression
2ms
The Impact of the Coexpression of MET and ESR Genes on Prognosticators and Clinical Outcomes of Breast Cancer: An Analysis for the METABRIC Dataset. (PubMed, Breast J)
Findings from our study add to the growing evidence on the potential crosstalk between MET and estrogen receptors in breast cancer. The expression of the MET/ESR genes could be a novel prognosticator and calls for future studies to evaluate the impact of combinational treatment approaches with MET inhibitors and endocrine drugs in breast cancer.
Clinical data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
HER-2 negative • MET expression
2ms
Reconfigurable Amphiphilic DNA Nanotweezer for Targeted Delivery of Therapeutic Oligonucleotides. (PubMed, ACS Cent Sci)
Moreover, this amphiphilic DNA nanotweezer shows enhanced accumulation at the tumor site and the inhibition of tumor growth. Taking advantage of the stimuli-responsive membrane anchoring capability, this reconfigurable DNA nanotweezer could be further explored as a smart multifunctional platform for cancer therapy.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
3ms
Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer. (PubMed, J Egypt Natl Canc Inst)
There is a possible correlation between c-MET and HER2 gene overexpression and poor clinical outcomes in patients with BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
HER-2 overexpression • HER-2 expression • MET overexpression • MET expression • MET overexpression + HER-2 overexpression
3ms
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity. (PubMed, Front Immunol)
This review also discusses the innovative cancer immunotherapies targeting c-MET, including chimeric antigen receptor (CAR) therapies, monoclonal antibodies, and antibody-drug conjugates, while encouraging the development of a comprehensive strategy that simultaneously tackles immune evasion and enhances anti-tumor efficacy further to improve the clinical prognoses for patients with c-MET-positive malignancies. Despite the challenges and variability in efficacy across different cancer subtypes, continued research into the molecular mechanisms and the development of innovative therapeutic strategies will be crucial.
Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
3ms
Hsa_circ_0009910 knockdown in HeLa cells increases miR‑198 expression levels and decreases c‑Met expression levels and cell viability. (PubMed, Oncol Lett)
The hsa_circ_0009910/miRNA-198/c-Met interaction network affects the viability, but not apoptosis, of HeLa cells. Based on this mechanism, the present study suggests that hsa_circ_0009910 may be a promising biomarker for CC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • MIR198 (MicroRNA 198)
|
MET expression
3ms
Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. (PubMed, Mol Cancer)
This study provides compelling evidence for the safety and efficacy of CAR-M therapy in treating pancreatic cancer. The results demonstrate that CAR-M-c-MET significantly suppresses pancreatic cancer progression and enhances the effectiveness of cytotoxic chemotherapy. Remarkably, no discernible side effects occur. Further clinical trials are warranted in human pancreatic cancer patients.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
3ms
Deoxycholic acid aggravates necrotizing enterocolitis through downregulation of mesenchymal-epithelial transition factor expression. (PubMed, Braz J Med Biol Res)
These findings indicated that MET mediated STAT3 involvement in intestinal epithelial cell proliferation and migration, demonstrating that the inhibitory effect of DCA on MET disrupted this process. These results elucidated the damaging effects and mechanisms of DCA accumulation in NEC, providing new insights into the use of DCA as a therapeutic target for NEC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
3ms
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET exon 14 mutation • MET expression
3ms
Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics. (PubMed, Mol Med)
CAR macrophages targeting c-Met represent a promising therapeutic strategy for pancreatic cancer, offering targeted elimination of CSCs and disruption of tumor angiogenesis. This study highlights the potential of single-cell multi-omics in guiding the development of precision immunotherapies.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • FGF2 (Fibroblast Growth Factor 2)
|
MET expression
4ms
Saikosaponin-b2 Regulates the Proliferation and Apoptosis of Liver Cancer Cells by Targeting the MACC1/c-Met/Akt Signalling Pathway. (PubMed, Adv Pharmacol Pharm Sci)
Additionally, the suppression of MACC1 activation by SS-b2 resulted in a reduction in the viability and proliferation of HepG2 liver cancer cells, and this reduction was comparable to that by doxorubicin (DOX)...Meanwhile, Annexin V-FITC/PI staining and western blot analysis of cleaved caspase 9 and cleaved caspase 3 demonstrated that SS-b2 induced apoptosis of HepG2 liver cancer cells. These findings provide experimental evidence suggesting that SS-b2 is a promising anticancer agent for liver cancer.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • MACC1 (MET Transcriptional Regulator MACC1) • ANXA5 (Annexin A5) • BAD (BCL2 Associated Agonist Of Cell Death)
|
MET expression
|
doxorubicin hydrochloride
4ms
Enhanced tumoricidal activity of PD-1 antibody-secreting c-Met CAR-T cells against pancreatic cancer cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
PD-1/c-Met CAR-T cells have higher killing efficiency against pancreatic cancer cells with also higher proliferative activity than c-Met CAR-T cells.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
PD-L1 expression • MET expression
4ms
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies. (PubMed, Curr Res Pharmacol Drug Discov)
This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease.
Review • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
4ms
Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer. (PubMed, Mol Pharm)
Our preclinical data suggest that the camelid antibody 1E7-Fc could be a potential theranostic agent for HNSCC. Further investigations are warranted to confirm these findings in patients and to evaluate 1E7-Fc as an imaging agent and platform to deliver radionuclide or drug therapy to MET-driven cancers.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET overexpression • MET expression
4ms
Targeting c-MET for Endoscopic Detection of Dysplastic Lesions Within Barrett's Esophagus Using EMI-137 Fluorescence Imaging. (PubMed, Clin Cancer Res)
EMI-137 accumulates in dysplastic lesions within BE and in c-MET positive EAC. EMI-137 imaging has potential as a screening and surveillance tool for patients with BE and as a means to detecting dysplasia and EAC.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • IL1B (Interleukin 1, beta)
|
MET overexpression • MET expression • MET positive
4ms
Cryotherapy in Nulliparous Women with Dysmenorrhea (clinicaltrials.gov)
P=N/A, N=180, Active, not recruiting, University of Malaga
New trial
|
MET expression
4ms
Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover. (PubMed, Cell Death Discov)
Overall, the research highlights the critical role of targeting c-Met to address osimertinib resistance in NSCLC. By demonstrating the efficacy of xanthohumol in overcoming resistance and enhancing therapeutic outcomes, this study provides valuable insights and potential new strategies for improving the clinical management of NSCLC.
Journal
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • ETS1 (ETS Proto-Oncogene 1) • USP9X (Ubiquitin Specific Peptidase 9 X-Linked)
|
EGFR mutation • MET overexpression • MET expression
|
Tagrisso (osimertinib)
5ms
Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth. (PubMed, Pharmaceuticals (Basel))
Overall, our data indicate that c-MET directly regulates NB growth and 3D spheroid growth, and c-MET inhibition by tivantinib may be an effective therapeutic approach for high-risk NB. Further developing c-MET targeted therapeutic approaches and combining them with current therapies may pave the way for effectively translating novel therapies for NB and other c-MET-driven cancers.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification • MET expression
|
tivantinib (ARQ 197)
5ms
CHRYSALIS-2: A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
P1, N=701, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=460 --> 701
Enrollment closed • Enrollment change
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation • EGFR expression + MET expression
|
Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
5ms
ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report. (PubMed, Transl Lung Cancer Res)
A 43-year-old, female diagnosed with T4N3M1c NSCLC harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variant 1 (EML4-ALK v.1) and TP53 co-mutation, displayed only mixed response after three months and highly symptomatic progression after 6 months of first-line brigatinib treatment. The latter may represent a mechanism of intrinsic ALK-TKI resistance and its recognition by FISH, in NGS-negative cases, may be considered before initiating first-line treatment. This recognition is clinically important as combined therapy with ALK-TKI and MET-inhibitor should be the preferred first-line treatment.
Journal • Metastases
|
ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
|
TP53 mutation • MET amplification • ALK rearrangement • MET overexpression • ALK fusion • MET expression
|
Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)
5ms
The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets. (PubMed, Curr Cancer Drug Targets)
The expression of the PD-L1 and MET genes is remarkably associated with worse tumor clinicopathologic features and poor prognosis in patients with breast cancer. Further investigations using combination drug regimens targeting PD-L1 and MET are important, particularly in breast tumors expressing high levels of both proteins.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
PD-L1 expression • HER-2 positive • PD-L1 overexpression • MET overexpression • HR negative • MET expression • HER-2 negative + HR negative + PD-L1 expression • HER-2 positive + HR negative • HR negative + HER-2 positive
5ms
A Phase I Study of SCC244 in Patients With Advanced MET Alterations Solid Tumors (clinicaltrials.gov)
P1, N=177, Completed, Haihe Biopharma Co., Ltd. | Unknown status --> Completed | N=75 --> 177
Trial completion • Enrollment change • Metastases
|
MET amplification • MET overexpression • MET expression
|
Haiyitan (gumarontinib)
5ms
Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression. (PubMed, Mol Oncol)
Finally, by performing a comparative transcriptomic analysis, we identify target genes that could play a relevant role in these cellular processes. Thus, our results demonstrate for the first time in prostate cancer models a functional interaction between ETS transcription factors (ETV1 and ERG) and MET signalling that confers more aggressive properties and highlight a molecular signature characteristic of this combined action.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • ETV1 (ETS Variant Transcription Factor 1)
|
MET expression
|
Tabrecta (capmatinib)
5ms
Selective inhibition of cancer cell migration using a pH-responsive nucleobase-modified DNA aptamer. (PubMed, Chem Sci)
CSL1-II in a weakly acidic environment had a stronger inhibitory effect on the HGF/c-Met pathway and exerted a strong controlling effect on the spreading and migration of cancer cells. Our strategy provides a simple and versatile method to develop pH-responsive DNA aptamers and represents the first example of a cancer-selective c-Met antagonist that inhibits cell migration.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET expression
5ms
TYRO3 and EPHA2 Expression Are Dysregulated in Breast Cancer. (PubMed, Cell Biochem Funct)
EPHA2 expression is also related to aging and smoking habits. The expression levels of the TAM and EPHA2 genes seem to play an important role in breast cancer, being also influenced by the patient's lifestyle.
Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • EPHA2 (EPH receptor A2) • TYRO3 (TYRO3 Protein Tyrosine Kinase)
|
MET expression
6ms
PREGMOUV: Physical Activity and Sedentary Behavior During Pregnancy (clinicaltrials.gov)
P=N/A, N=630, Recruiting, University Hospital, Clermont-Ferrand | Not yet recruiting --> Recruiting
Enrollment open
|
MET expression
6ms
Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. (PubMed, Mol Biomed)
Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.
Preclinical • Journal • Oncolytic virus • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase) • CD40LG (CD40 ligand)
|
MET overexpression • MET expression
6ms
R5093-ONC-1863: A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=231, Active, not recruiting, Regeneron Pharmaceuticals | N=82 --> 231 | Trial completion date: Oct 2024 --> Jan 2032 | Trial primary completion date: Oct 2024 --> Jan 2032
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression • MET elevation
|
davutamig (REGN5093)
6ms
c-MET is an important marker for acid-driven metastasis and anti-immune in colorectal cancer. (PubMed, Int Immunopharmacol)
MET is an important contributor to acid-driven colorectal cancer metastasis and participates in immune escape of colorectal cancer. It is of great significance for the prognosis and immunotherapy of colorectal cancer and some other cancers.
Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8)
|
MET expression